Merck-Moderna Cancer Vaccine Breakthrough Sparks Biotech Rally

The recent breakthrough in cancer vaccine research has sent shockwaves through the biotech industry. A Phase 3 trial involving Merck (NYSE:MRK) and Moderna (NASDAQ:MRNA)'s intismeran autogene showed promising results, beating Keytruda alone on recurrence-free survival in melanoma patients.

The treatment, which pairs an individualized neoantigen therapy with Keytruda, has the potential to be a game-changer for cancer patients. The success of this trial is crucial for Merck, as it faces a patent cliff in 2028 and needs a new revenue stream. Moderna also stands to benefit from a successful treatment.

The development of individualized neoantigen therapies requires sequencing a patient's tumor and running a bespoke manufacturing batch. This drives demand for sequencing capacity and bioprocessing consumables on a per-patient basis. As a result, several companies are poised to benefit if this therapy reaches the market.